Clinical trial NCT00086684: Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Official title: Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Interstitial Cystitis
Keywords: Interstitial Cystitis
Urinary Bladder Pain
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor class: INDUSTRY
First posted: 2004-07-09
Enrollment: 369
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.

Detailed description: The purpose of this multi-center, double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance), parallel group trial is to evaluate the effectiveness and safety of two doses of pentosan polysulfate sodium (100 mg once a day and 100 mg three times a day) versus placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis. The hypothesis of the study is that there is no treatment difference in the proportion of responders at study endpoint (Week 24). Effectiveness will be assessed based on the reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) total score. Safety assessments include vital signs, laboratory tests, adverse events and physical exams. Patients will receive one of the following study treatments by mouth each day for 24 weeks: pentosan polysulfate sodium 100 mg once a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, and one matching placebo capsule in the afternoon and evening; pentosan polysulfate sodium 100 mg capsule three times a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, afternoon and evening; placebo group - one placebo capsule in the morning, afternoon and evening

Eligibility criteria: Inclusion Criteria:

* Must have a total score of 8 or greater on the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and a score of \> 0 on each of the 4 questions on the ICSI
* must have experienced bladder pain, urinary urgency and urinary frequency, each not related to a urinary tract infection, for at least 6 months prior to entry into the study
* must have averaged \>= 10 voids per day (\>=30 voids over 3 consecutive days) and averaged \>= 1 void at night
* urine culture showing no evidence of urinary tract infection
* urine cytology showing no evidence of neoplastic cells

Exclusion Criteria:

* Scheduled for or use of intravesical therapy (eg, bladder distention, dimethyl sulfoxide) during or within 4 weeks prior to the study
* patients who have had cytoscopic evaluation within 4 weeks prior to the study
* patients who are currently (within last month) receiving other medications that may affect symptoms of interstitial cystitis (ie, antidepressants, antihistamines, antispasmodics, anticholinergics)
* patients who are chronic users of Schedule II narcotics or who are using any scheduled narcotics at the time of study entry
* patients taking coumadin, anticoagulants, heparin, or thrombolytic agents such as tissue plasminogen activator and streptokinase

Primary outcomes:
measure: Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint
timeFrame: Baseline to Week 24
Secondary outcomes:
measure: Number of Responders Defined as Having at Least a Four Point Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint
timeFrame: Baseline to Week 24
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Homewood
country: United States
state: Alabama
city: Anchorage
country: United States
state: Alaska
city: San Bernardino
country: United States
state: California
city: San Carlos
country: United States
state: California
city: San Diego
country: United States
state: California
city: Torrance
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Longmont
country: United States
state: Colorado
city: Wheat Ridge
country: United States
state: Colorado
city: Newington
country: United States
state: Connecticut
city: Norwalk
country: United States
state: Connecticut
city: Celebration
country: United States
state: Florida
city: Longwood
country: United States
state: Florida
city: Plantation
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Trinity
country: United States
state: Florida
city: Venice
country: United States
state: Florida
city: Weston
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Centralia
country: United States
state: Illinois
city: Evanston
country: United States
state: Illinois
city: Peoria
country: United States
state: Illinois
city: Jeffersonville
country: United States
state: Indiana
city: Dearborn
country: United States
state: Michigan
city: Grand Rapids
country: United States
state: Michigan
city: Kalamazoo
country: United States
state: Michigan
city: Saint Louis
country: United States
state: Missouri
city: Henderson
country: United States
state: Nevada
city: West Orange
country: United States
state: New Jersey
city: Albany
country: United States
state: New York
city: Charlotte
country: United States
state: North Carolina
city: Concord
country: United States
state: North Carolina
city: Winston Salem
country: United States
state: North Carolina
city: Lima
country: United States
state: Ohio
city: Ponca City
country: United States
state: Oklahoma
city: Tulsa
country: United States
state: Oklahoma
city: Medford
country: United States
state: Oregon
city: Portland
country: United States
state: Oregon
city: Philadelphia
country: United States
state: Pennsylvania
city: Nashville
country: United States
state: Tennessee
city: Arlington
country: United States
state: Texas
city: Austin
country: United States
state: Texas
city: Carrollton
country: United States
state: Texas
city: Fort Worth
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Ogden
country: United States
state: Utah
city: Salt Lake City
country: United States
state: Utah
city: Richmond
country: United States
state: Virginia
city: Mountlake Terrace
country: United States
state: Washington
city: Seattle
country: United States
state: Washington
city: Milwaukee
country: United States
state: Wisconsin
city: Edmonton
country: Canada
state: Alberta
city: Kelowna
country: Canada
state: British Columbia
city: Surrey
country: Canada
state: British Columbia
city: Victoria
country: Canada
state: British Columbia
city: Fredericton
country: Canada
state: New Brunswick
city: Halifax
country: Canada
state: Nova Scotia
city: Kentville
country: Canada
state: Nova Scotia
city: Barrie
country: Canada
state: Ontario
city: Burlington
country: Canada
state: Ontario
city: Kingston
country: Canada
state: Ontario
city: Kitchener
country: Canada
state: Ontario
city: Newmarket
country: Canada
state: Ontario
city: Toronto
country: Canada
state: Ontario
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Imamura M, Scott NW, Wallace SA, Ogah JA, Ford AA, Dubos YA, Brazzelli M. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. Cochrane Database Syst Rev. 2020 Jul 30;7(7):CD013325. doi: 10.1002/14651858.CD013325.pub2.